You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

 

1713 Results
Regimen
Cancer Type:
Genitourinary, 
Bladder / Urothelial
Intent: Neoadjuvant, Adjuvant, Palliative
Sep 2022
Regimen
Cancer Type:
Gynecologic, 
Endometrial
Intent: Palliative
Oct 2023
Regimen
Cancer Type:
Gynecologic, 
Gestational Trophoblastic Disease
Intent: Curative
Dec 2025
Regimen
Cancer Type:
Genitourinary, 
Bladder / Urothelial
Intent: Palliative
Jan 2024
Regimen
Cancer Type:
Lung, 
Non-Small Cell
Intent: Adjuvant
Jun 2019
Regimen
Cancer Type:
Central Nervous System
Intent: Adjuvant
Funding:
ODB - General Benefit
    temozolomide
Aug 2025
Regimen
Intent: Palliative
Nov 2024
Regimen
Cancer Type:
Lung, 
Non-Small Cell
Intent: Neoadjuvant, Adjuvant
Jun 2019
Regimen
Cancer Type:
Lung, 
Non-Small Cell
Intent: Palliative
Funding:
New Drug Funding Program
    Pembrolizumab - In Combination with Platinum and Pemetrexed for First Line Metastatic Non-Squamous Non-Small Cell Lung Cancer (NSCLC)
Aug 2022
Regimen
Cancer Type:
Hematologic, 
Lymphoma - Hodgkin
Intent: Curative
Funding:
New Drug Funding Program
    Brentuximab Vedotin - In Combination with Chemotherapy for Previously Untreated Advanced Stage Hodgkin Lymphoma
Jun 2025
Regimen
Intent: Neoadjuvant
Funding:
New Drug Funding Program
    Pembrolizumab - Previously Untreated High-Risk Early-Stage Triple Negative Breast Cancer
Sep 2023

Pages